A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 101–200 of 1,002
Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model
Fol, R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S. W., Roederer, J.-P., Brod, F., Audrain, M., Bemelmans, A.-P., Buchholz, C. J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1498-9 · Cited by 168
The γ-secretase complex: from structure to function
Zhang, X., Li, Y., Xu, H., & Zhang, Y.-W. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00427 · Cited by 160
“In a phase III clinical trial of the GSI semagacestat, it was found that semagacestat not only had no effect on improving cognitive status, but also was associated with more adverse events including skin cancers and infections, compared to placebo controls (Doody et al., 2013).”
BackgroundTargeting Amyloidogenic Processing of APP in Alzheimer’s Disease
Zhao, J., Liu, X., Xia, W., Zhang, Y., & Wang, C. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00137 · Cited by 162
Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
The Toxicity and Polymorphism of β-Amyloid Oligomers
Huang, Y.-R., & Liu, R.-T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124477 · Cited by 159
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
“Drug-related reasons for negative trials include lack of efficacy and excessive toxicity [106].”
BackgroundThe present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Precision drug delivery to the central nervous system using engineered nanoparticles
Gao, J., Xia, Z. J., Gunasekar, S., Jiang, C., Karp, J. M., & Joshi, N. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00695-w · Cited by 184
The Regulation of Astrocytic Glutamate Transporters in Health and Neurodegenerative Diseases
Todd, A. C., & Hardingham, G. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249607 · Cited by 172
“The failed results of the semagacestat drug trial, that worsened disease progression, certainly hint that blocking Notch signalling and perhaps reducing EAAT function exacerbate neurodegenerative disease [222,229].”
ResultSecretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
Kumar, D., Ganeshpurkar, A., Kumar, D., Modi, G., Gupta, S. K., & Singh, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.035 · Cited by 170
Han, Y., Chu, X., Cui, L., Fu, S., Gao, C., Li, Y., & Sun, B. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1745328 · Cited by 156
“Unfortunately, almost all the Ab-targeting drug candidates have failed in clinical trials (Doody et al., 2013, 2014; Salloway et al., 2014).”
BackgroundThe ethics of placebo-controlled trials: Methodological justifications
Millum, J., & Grady, C. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.09.003 · Cited by 155
Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape
Guo, L., Zhong, M. B., Zhang, L., Zhang, B., & Cai, D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.968 · Cited by 164
“Surprisingly, sex-specific analyses were only performed occasionally during AD clinical trial phases, and the importance of considering sex as a critical modulator of patient responses to treatments was vastly underappreciated (3-6).”
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S. K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159
Wang, Z.-Y., Liu, J.-G., Li, H., & Yang, H.-M. (2016) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x16500853 · Cited by 161
Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease
Goyal, D., Kaur, A., & Goyal, B. (2018) · ChemMedChem · doi:10.1002/cmdc.201800156 · Cited by 168
Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease
Arbo, B. D., André-Miral, C., Nasre-Nasser, R. G., Schimith, L. E., Santos, M. G., Costa-Silva, D., Muccillo-Baisch, A. L., & Hort, M. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00103 · Cited by 154
The Humanistic and Economic Burden of Alzheimer's Disease
Monfared, A. A. T., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00335-x · Cited by 171
“A study of patients with mild AD and with (n = 113) or without diabetes (n = 859) showed that after 18 months, while there was no difference between the groups in terms of changes in cognition or QoL (on the QoL-AD or EQ-5D), patients with AD and comorbid diabetes had significantly less deterioration in ADLs [49, 50].”
BackgroundFujita, K., Motoki, K., Tagawa, K., Chen, X., Hama, H., Nakajima, K., Homma, H., Tamura, T., Watanabe, H., Katsuno, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31895 · Cited by 160
Doubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 155
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 148
Cryo-EM structure of gamma secretase in complex with a Notch fragment: 6idf
Yang, G., Zhou, R., Zhou, Q., Guo, X., Yan, C., Ke, M., Lei, J., & Shi, Y. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6idf/pdb · Cited by 154
Gao, C., Wang, Y., Sun, J., Yang, H. N., Gong, W., Li, Y., Feng, Y., Wang, H., Yang, M., Li, Z., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.029 · Cited by 162
Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt246 · Cited by 153
“Many new candidate drugs are targeting the production, aggregation, or clearance of Aβ such as γ-secretase inhibitors [14,15] and β-secretase inhibitors [16-18].”
BackgroundAlzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
Ferretti, M. T., Martinkova, J., Biskup, E., Benke, T., Gialdini, G., Nedelska, Z., Rauen, K., Mantua, V., Religa, D., Hort, J., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14174 · Cited by 147
Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., & Chen, N. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02753-6 · Cited by 162
“Many developed drugs have not shown the positive therapeutic effects on AD patients and even can cause severe adverse reactions, such as meningitis [31] and cognitive impairment [32].”
BackgroundGocho, Y., Liu, J., Hu, J., Yang, W., Dharia, N. V., Zhang, J., Shi, H., Du, G., John, A., Lin, T.-N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00167-4 · Cited by 153
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162
Self-citationPhysiology and pharmacology of amyloid precursor protein
Cho, Y., Bae, H.-G., Okun, E., Arumugam, T. V., & Jo, D.-G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108122 · Cited by 142
Rajasekhar, K., & Govindaraju, T. (2018) · RSC Advances · doi:10.1039/c8ra03620a · Cited by 150
Predicting the frequencies of drug side effects
Galeano, D., Li, S., Gerstein, M., & Paccanaro, A. (2020) · Nature Communications · doi:10.1038/s41467-020-18305-y · Cited by 156
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
The amyloid-beta forming tripeptide cleavage mechanism of γ-secretase
Bolduc, D. M., Montagna, D. R., Seghers, M. C., Wolfe, M. S., & Selkoe, D. J. (2016) · eLife · doi:10.7554/elife.17578 · Cited by 139
“DOI: 10.7554/eLife.17578 12 of 21 A species Tripeptides AICD E + S ES ES* ES + P E + P ES ES* ES ES* [ ]n P S E N P S E N P S E N P S E N A C D Notch TMD: S3S4 B 1) 2) 3) A 40 A 42 Pathway N- -”
BackgroundInfluentialGamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J.-F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 137
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 155
Iwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., Senda, M., Ito, K., Ikeuchi, T., Kuwano, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.009 · Cited by 141
Self-citationXu, M., Mo, X., Huang, H., Chen, X., Liu, H., Peng, Z., Chen, L., Rong, S., Yang, W., Xu, S., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.180 · Cited by 137
Adenosine Receptor Control of Cognition in Normal and Disease
Chen, J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00012-x · Cited by 152
Dementia risk and prevention by targeting modifiable vascular risk factors
Tariq, S., & Barber, P. A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 136
Awasthi, M., Singh, S., Pandey, V. P., & Dwivedi, U. N. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.008 · Cited by 147
“monobenzocaprolactam) γ-Secretase inhibition Terminated in Phase III Increased risk of skin cancer and infection [12,42]”
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E.-K., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 125
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L.-H. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 127
“A number of promising drugs have reached late-stage (Phase III) clinical testing, however then failed to prevent cognitive decline (Doody et al., 2013; Doody et al., 2014; Salloway et al., 2014).”
BackgroundGamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance
McCaw, T. R., Inga, E. E., Chen, H., Jaskula‐Sztul, R., Dudeja, V., Bibb, J. A., Ren, B., & Rose, J. B. (2021) · The Oncologist · doi:10.1002/onco.13627 · Cited by 144
“Adverse events and lack of efficacy limited the utility of these agents [3, 4], but a shared proteolytic processing pathway between amyloid beta and the Notch family has been implicated in off-target effects [5].”
BackgroundBiometals and Their Therapeutic Implications in Alzheimer's Disease
Ayton, S., Lei, P., & Bush, A. I. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0312-z · Cited by 142
“Most prominently, phase 3 trials have been performed on drugs that lower Aβ by inhibiting its production [7, 8] and lowering its levels by immunotherapy [9, 10], all of which failed to reach their respective clinical endpoints.”
BackgroundThe Benzodiazepine–Dementia Disorders Link: Current State of Knowledge
Pariente, A., de Gage, S. B., Moore, N. D., & Bégaud, B. (2015) · CNS Drugs · doi:10.1007/s40263-015-0305-4 · Cited by 144
“Interestingly, some benzodiazepine derivatives demonstrated an inhibitory effect on c-secretase, but this did not result in any positive effect on lesions or symptoms when these products were experimentally tested [29], some even being found to have deleterious effects on cognition outcomes in phase III randomised tri…”
BackgroundBACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M. A., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 126
“Two key -secretase inhibitors (GSIs), semagacestat (1) from Eli Lilly & Co and later avagacestat (2) from Bristol-Myers Squibb (Figure 6) advanced in latestage clinical trials for AD (phase III and phase II, respectively) [39,40].”
BackgroundMaking the final cut: Pathogenic amyloid-β peptide generation by γ-secretase
Steiner, H., Fukumori, A., Tagami, S., & Okochi, M. (2018) · Cell Stress · doi:10.15698/cst2018.11.162 · Cited by 133
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Three-dimensional modeling of human neurodegeneration: brain organoids coming of age
Grenier, K., Kao, J., & Diamandis, P. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0500-7 · Cited by 133
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 124
“Two essential phase III clinical trials were hesitantly commenced, and subsequently discontinued as a result of a lack of efficacy, increased risk of the skin infection, and cancer [155].”
Backgroundγ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
Ran, Y., Hossain, F., Pannuti, A., Lessard, C. B., Ladd, G. Z., Jung, J. I., Minter, L. M., Osborne, B. A., Miele, L., & Golde, T. E. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607265 · Cited by 128
“…of AD patients with current GSIs appears unfeasible due to side effects that limit the maximum tolerable dose to the point where the extent of long-term Ab lowering is likely to be insufficient to have clinical impact (Cummings, 2010; Extance, 2010; Samson, 2010; Schor, 2011; Doody et al, 2013).”
BackgroundThe amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 139
Majdi, A., Sadigh-Eteghad, S., Rahigh Aghsan, S., Farajdokht, F., Vatandoust, S. M., Namvaran, A., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 122
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
Self-citationWang, J., Bi, W., Cheng, A., Freire, D., Vempati, P., Zhao, W., Gong, B., Janle, E. M., Chen, T.-Y., Ferruzzi, M. G., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00042 · Cited by 125
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 117
Alzheimer's disease failed clinical trials
Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2018) · Neurología · doi:10.1016/j.nrl.2015.03.012 · Cited by 97
Structure and Function of the γ-Secretase Complex
Wolfe, M. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00401 · Cited by 116
Olfactory Identification Deficits, Cognitive Decline, and Dementia in Older Adults
Devanand, D. P. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.08.010 · Cited by 127
An update on the novel and approved drugs for Alzheimer disease
Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122
“…of skin cancer, while avagacestat was linked to a higher percentage of cognitive decline as well as adverse dose-limiting effects such as the incidence of skin cancer while tarenflurbil had little blood–brain barrier penetration (Doody et al., 2013; Coric et al., 2015; Muntimadugu et al., 2016).”
Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Vico Varela, E., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 118
Calcium Signaling in ß-cell Physiology and Pathology: A Revisit
Klec, C., Ziomek, G., Pichler, M., Malli, R., & Graier, W. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246110 · Cited by 134
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 126
Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques
Pensalfini, A., Albay, R., Rasool, S., Wu, J. W., Hatami, A., Arai, H., Margol, L., Milton, S., Poon, W. W., Corrada, M. M., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.011 · Cited by 120
Tanaka, H., Homma, H., Fujita, K., Kondo, K., Yamada, S., Jin, X., Waragai, M., Ohtomo, G., Iwata, A., Tagawa, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14353-6 · Cited by 119
Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond
De Strooper, B., & Chávez Gutiérrez, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124309 · Cited by 119
“It tested the γsecretase inhibitor (GSI) semagacestat in a large cohort of patients with probable AD (8).”
Doniger, G. M., Beeri, M. S., Bahar‐Fuchs, A., Gottlieb, A., Tkachov, A., Kenan, H., Livny, A., Bahat, Y., Sharon, H., Ben‐Gal, O., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.02.005 · Cited by 112
The therapeutics of Alzheimer's disease: Where we stand and where we are heading
Selkoe, D. J. (2013) · Annals of Neurology · doi:10.1002/ana.24001 · Cited by 113
“Accordingly, some subjects developed serious side effects apparently attributable to decreasing the processing of Notch and perhaps other c-substrates besides APP.1 The worsening of cognitive performance seen in some patients in this aborted trial may have been due to these side effects; there is no current evidence t…”
BackgroundFamilial Alzheimer’s disease mutations in PSEN1 lead to premature human stem cell neurogenesis
Arber, C., Lovejoy, C., Harris, L., Willumsen, N., Alatza, A., Casey, J. M., Lines, G., Kerins, C., Mueller, A. K., Zetterberg, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108615 · Cited by 116
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
“F or p er so na l u se o nl y. BACE1: β-site APP cleaving enzyme 1 semagacestat (Doody et al. 2013)], decreasing Aβ aggregation [by using deaggregating compounds, e.g., tramiprosate (Aisen et al. 2012)], or favoring Aβ clearance [by immunotherapy, e.g., solanezumab (Siemers et al. 2015)] (Figure 1,…”
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases
CHRISTOPOULOS, P. F., Gjølberg, T. T., Krüger, S., Haraldsen, G., Andersen, J. T., & Sundlisæter, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668207 · Cited by 117
“A phase 3 trial of the GSI semagacestat (NCT00594568), also developed initially for treatment of Alzheimer’s disease, was terminated before completion due to lack of clinical efficacy and safety concerns (59).”
BackgroundKumar, V., Kim, S.-H., & Bishayee, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179540 · Cited by 124
Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy
Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020) · International Journal of Alzheimer's Disease · doi:10.1155/2020/5380346 · Cited by 107
“Semagacestat [65] III Toxicity and lack of efficacy Worsens cognition”
BackgroundMethodPrecision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
Sanati, M., Khodagholi, F., Aminyavari, S., Ghasemi, F., Gholami, M., Kebriaeezadeh, A., Sabzevari, O., Hajipour, M. J., Imani, M., Mahmoudi, M., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00622 · Cited by 112
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo-Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H., Bravo, J., Brendza, R., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 110
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease
Popugaeva, E., & Bezprozvanny, I. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00029 · Cited by 106
“One of the main therapeutic approaches to AD is focused on development of γ-secretase inhibitors (GSIs) and modulators, however so far this approach has failed in phase III clinical trials of Eli–Lilly’s Semagacestat, a non-selective GSI (Doody et al., 2013).”
BackgroundBordet, R., Ihl, R., Korczyn, A. D., Lanza, G., Janša, J., Hoerr, R., & Guekht, A. B. (2017) · BMC Medicine · doi:10.1186/s12916-017-0869-6 · Cited by 112
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2018) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.03.019 · Cited by 101
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition
Habets, R., de Bock, C. E., Serneels, L., Lodewijckx, I., Verbeke, D., Nittner, D., Narlawar, R., Demeyer, S., Dooley, J., Liston, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6246 · Cited by 115
Cimenser, A., Hempel, E., Travers, T., Strozewski, N., Martin, K., Malchano, Z., & Hajós, M. (2021) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2021.746859 · Cited by 107
Zhu, H., Wang, X., Wallack, M., Li, H., Carreras, I., Dedeoglu, A., Hur, J.-Y., Zheng, H., Li, H., Fine, R., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.17 · Cited by 108
Self-citationThe Genetics of Hidradenitis Suppurativa
Ingram, J. R. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2015.07.002 · Cited by 107
Stem Cell Therapy for Alzheimer’s Disease: A Review of Recent Clinical Trials
Kang, J. M., Yeon, B. K., Cho, S., & Suh, Y. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160406 · Cited by 111
Iliyasu, M. O., Musa, S. A., Oladele, S. B., & Iliya, A. I. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1081938 · Cited by 111
“, 2019), as well as the anti-amyloid agents such as semagacestat (Doody et al., 2013), bapineuzumab (Vandenberghe et al.”
BackgroundIraji, A., Khoshneviszadeh, M., Firuzi, O., Khoshneviszadeh, M., & Edraki, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103649 · Cited by 110
The Role of Mitochondrial Calcium Homeostasis in Alzheimer’s and Related Diseases
Ryan, K. C., Ashkavand, Z., & Norman, K. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239153 · Cited by 114
“Indeed, the use of immunotherapies targeting Abeta, some of which have been shown to bind oligomeric Abeta with high affinity, have no effect on disease progression [8,13].”
BackgroundHoffmann, M., Stiller, C., Endres, E., Scheiner, M., Gunesch, S., Sotriffer, C., Maurice, T., & Decker, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01012 · Cited by 105
He, Q., Chen, X., Wu, T., Li, L., & Fei, X. (2019) · Journal of Clinical Neurology · doi:10.3988/jcn.2019.15.1.9 · Cited by 95
Fang, F., Yu, Q., Arancio, O., Chen, D., Gore, S. S., Yan, S. S., & Yan, S. F. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy017 · Cited by 103
Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings
Henley, D. B., Sundell, K. L., Sethuraman, G., Dowsett, S. A., & May, P. C. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.939167 · Cited by 98
Self-citationSelective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Greenough, M. A., Lane, D. J. R., Balez, R., Anastacio, H. T. D., Zeng, Z., Ganio, K., McDevitt, C. A., Acevedo, K., Belaidi, A. A., Koistinaho, J., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01003-1 · Cited by 102
“Finally, a γ-secretase-inhibitor caused accelerated cognitive decline and other intolerable side effects that resulted in the early termination of clinical testing in over 3000 AD patients [18].”
BackgroundAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S.-D., Chougule, M., Shoyele, S. A., Gupta, U., Ajazuddin, et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101
“There are some drug molecules which selectively reduces the amyloid plaque formation like tarenflurbil [19], semagacestat (γ-secretase inhibitor) [20], solenezumab [21], and aducanumab (anti-Aβ antibody) [22] etc.”
BackgroundAccelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 97
Alzheimer's disease: The amyloid hypothesis on trial
Harrison, J. R., & Owen, M. J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.167569 · Cited by 96
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.